

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Heinrich REPKE et al.

Serial No.: 10/059,271 Group Art Unit: 1645

Filed: January 31, 2002 Examiner: Unassigned

For: PROTEIN HAVING MULTIPLE ANTIGEN/EPITOPE SEQUENCES AND BEING

**IMMOBILIZED** 

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98 **Assistant Commissioner for Patents** RECEIVED Washington, D. C. 20231 OCT 1 1 2002 Sir: **TECH CENTER 1600/2900 CITED MATERIALS** Applicant(s) hereby disclose the information listed in the attached form PTO-1449. Copies of materials listed but not attached were cited in parent application Serial No. \_\_\_\_; see 37 C.F.R. § 1.98(d). Copies of materials listed but not attached were cited in an International Search Report dated \_\_\_\_\_; receipt of the International Search Report and copies of references was confirmed by the PCT International Division of the U.S. PTO in the Notice of Acceptance mailed . ADDITIONAL INFORMATION LANGUAGE All listed materials are in the English language; see 37 C.F.R. § 1.98. Non-English language references: 

The reference(s):

commercial data bases to correspond to the reference(s):

provided.

A commercial English-language abstract of reference(s) is (are) provided.

An English-language search report or an equivalent paper from a foreign patent office translated into English in pertinent part in connection with a counterpart foreign application, is provided indicating the relevance of the cited reference(s).

(An) English-language translation(s) of the references:

in the English-language is (are) indicated by

, respectively.

is (are)

## $\underline{\mathsf{FEES}}$

 $\boxtimes$ 

	within	This Information Disclosure Statement is being filed within three months filing date of a national application (other than a CPA) under § 1.53(d) or 3 months of the date of entry of the national stage under § 1.491 in an ational application;
	⊠ a first a	This Information Disclosure Statement is being filed before the mailing of action on the merits;
	notice	This Information Disclosure Statement is being filed after a first action on crits but before the mailing date of any of a final action under § 1.113, a of allowance under § 1.311, or an action that closes prosecution in the ation, and is accompanied by a certification below.
		This Information Disclosure Statement is filed under 37 C.F.R. § 1.97(i).
	A fee i	s required for this Information Disclosure Statement:
	notice	This Information Disclosure Statement is being filed after a first action on crits but before the mailing date of any of a final action under § 1.113, a of allowance under § 1.311 or an action that closes prosecution, and is panied by the fee set forth in §1.17(p).
	prosec	This Information Disclosure Statement is being filed after the mailing date all rejection or a notice of allowance under § 1.311 or an action that closes ution, but before the payment of the issue fee, and is accompanied by the forth in § 1.17(p) and a certification below.
CERT	IFICAT	ION
	cited in	em of information contained in this Information Disclosure Statement was a communication from a foreign patent office in a counterpart foreign ation not more than three months prior to the filing of this statement.
	cited in applicating	m of information contained in this Information Disclosure Statement was a communication from a foreign patent office in a counterpart foreign ation and, to the knowledge of the undersigned, having made reasonable y, no such item was known to any individual designated in 37 CFR § 1, more than three months prior to the filing of this statement.

No fee is required for this Information Disclosure Statement because:

## **DEPOSIT ACCOUNT**

If a fee is due, attached is a check in the amount of <u>\$</u>. However, the Commissioner is hereby authorized to charge fees under 37 CFR § 1.16 and § 1.17 which may be required to facilitate this filing, or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,

Anthony J. Zerano, Reg. No. 27,969 Attorney/Agent for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C. Arlington Courthouse Plaza l 2200 Clarendon Blvd. Suite 1400 Arlington, Virginia 22201 Telephone: (703) 243-6333

Facsimile: (703) 243-6410

Attorney Docket No.: ALBRE-22

Date: October 9, 2002

AJZ:jr

OCT 0 9 2002

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office. U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO Complete if Known 10/059,271 Application Number INFORMATION DISCLOSURE January 31, 2002 Filing Date STATEMENT BY APPLICANT Heinrich REPKE et al. First Named Inventor 1645 Group Art Unit (use as many sheets as necessary) Examiner Name Unassigned Sheet of Attorney Docket Number ALBRE-22

		IENTS	U.S. PATENT DOCUM				
elevant	Pages, Columns, Lines. Where Relevant Passages or Relevant Figures Appear	Date of Publication of Cited Document MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	U.S. Patent Document  Kind Code <sup>2</sup> Number		Cite No 1	Examiner Initials *
<del></del>	, iguies i ipped	09/14/1999	SIA et al.	OWN)	5,951,986	ļ	
		08/31/1993	LACROIX	Â	5,241,047		
EIVE	RECI						
	OCT 1						
<del></del>	TECH CENT						
	,						
		-, -, -, -, -, -, -, -, -, -, -, -, -, -				ļ <u>.</u>	

FOREIGN PATENT DOCUMENTS								
		Foreign Patent Document			Name of Patentee	Date of Publication of	Pages, Columns, Lines, Where Relevant	
Examiner Initials*	Cite No. <sup>1</sup>	Office <sup>3</sup>		nd Code <sup>5</sup> f known)	or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	Т6
		WO	01 96870	Α		12/20/2001		
		EP	0 940 470	Α		09/08/1999		
		EP	0 307 149	Α		03/15/1989		
		<del> </del>						<del> </del>
		1						

_			
	Examiner Signature	Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.